EDITAS MEDICINE INC (EDIT) — insider trading
Health Care · NASDAQ
EDITAS MEDICINE INC (EDIT) has 19 reported SEC Form 4 insider transactions in our data, including 9 open-market sales among the most recent 19 (latest 2026-09-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Ory Daniel Scott | Officer (EVP, Chief Medical Officer) | Grant / award / vesting (derivative) | 950,000 | — | $0 | Form 4 |
| 2026-09-03 | Parison Amy | Officer (SVP, Chief Financial Officer) | Open-market sale | 453 | $3.04 | $1.4K | Form 4 |
| 2026-09-03 | O'Neill Gilmore Neil | Director, Officer (CEO) | Open-market sale | 5,124 | $3.04 | $15.6K | Form 4 |
| 2026-09-03 | Burkly Linda | Officer (EVP, CHIEF SCIENTIFIC OFFICER) | Open-market sale | 709 | $3.04 | $2.2K | Form 4 |
| 2026-08-06 | Ellinor Patrick Thomas II | Director | Grant / award / vesting (derivative) | 103,400 | — | $0 | Form 4 |
| 2026-08-03 | Parison Amy | Officer (SVP, Chief Financial Officer) | Open-market sale | 678 | $2.58 | $1.7K | Form 4 |
| 2026-07-28 | Burkly Linda | Officer (EVP, CHIEF SCIENTIFIC OFFICER) | Open-market sale | 4,928 | $2.67 | $13.2K | Form 4 |
| 2026-06-17 | Levy Elliott M. | Director | Grant / award / vesting (derivative) | 51,700 | — | $0 | Form 4 |
| 2026-06-17 | Scadden David | Director | Grant / award / vesting (derivative) | 51,700 | — | $0 | Form 4 |
| 2026-06-17 | Hirsch Andrew | Director | Grant / award / vesting (derivative) | 51,700 | — | $0 | Form 4 |
| 2026-06-17 | Hopfield Jessica | Director | Grant / award / vesting (derivative) | 51,700 | — | $0 | Form 4 |
| 2026-06-17 | Connaughton Bernadette | Director | Grant / award / vesting (derivative) | 51,700 | — | $0 | Form 4 |
| 2026-06-03 | Burkly Linda | Officer (EVP, CHIEF SCIENTIFIC OFFICER) | Open-market sale | 731 | $2.70 | $2.0K | Form 4 |
| 2026-06-03 | O'Neill Gilmore Neil | Director, Officer (CEO) | Open-market sale | 15,380 | $2.70 | $41.5K | Form 4 |
| 2026-06-03 | Parison Amy | Officer (SVP, Chief Financial Officer) | Open-market sale | 464 | $2.70 | $1.3K | Form 4 |
| 2026-03-12 | Burkly Linda | Officer (EVP, CHIEF SCIENTIFIC OFFICER) | Grant / award / vesting (derivative) | 292,856 | — | $0 | Form 4 |
| 2026-03-12 | Parison Amy | Officer (SVP, Chief Financial Officer) | Grant / award / vesting (derivative) | 292,856 | — | $0 | Form 4 |
| 2026-03-12 | O'Neill Gilmore Neil | Director, Officer (CEO) | Grant / award / vesting (derivative) | 1,015,200 | — | $0 | Form 4 |
| 2026-03-03 | O'Neill Gilmore Neil | Director, Officer (CEO) | Open-market sale | 5,394 | $2.02 | $10.9K | Form 4 |
Ask the chat about EDIT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: EDITAS MEDICINE INC (EDIT).
Last updated 2026-09-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.